tiprankstipranks
Advertisement
Advertisement

ELVN Stock Latest News

Enliven price target raised to $55 from $36 at Clear Street
The FlyEnliven price target raised to $55 from $36 at Clear Street
3d ago
ELVN
Enliven Therapeutics: Strengthening ELVN-001 Profile and M&A Optionality Support Buy Rating and $56 Price Target
PremiumRatings
Enliven Therapeutics: Strengthening ELVN-001 Profile and M&A Optionality Support Buy Rating and $56 Price Target
22d ago
ELVN
Leveraging Merck–Terns Benchmark: Supporting Enliven’s ELVN-001 Upside and a Raised $60 Buy Target
PremiumRatings
Leveraging Merck–Terns Benchmark: Supporting Enliven’s ELVN-001 Upside and a Raised $60 Buy Target
23d ago
ELVN
Enliven rises 11.0%
PremiumThe Fly
Enliven rises 11.0%
1M ago
ELVN
Enliven price target raised to $56 from $48 at H.C. Wainwright
PremiumThe Fly
Enliven price target raised to $56 from $48 at H.C. Wainwright
1M ago
ELVN
Clear Street says Merck’s bet on TERN-701 sharpens investment case for ELVN-001
PremiumThe FlyClear Street says Merck’s bet on TERN-701 sharpens investment case for ELVN-001
1M ago
MRK
NVS
Video: Arm jumps as analysts react favorably to business model shift, guidance
Premium
The Fly
Video: Arm jumps as analysts react favorably to business model shift, guidance
1M ago
ARM
MRK
Enliven up 20% after Terns Pharmaceuticals agrees to be bought by Merck
Premium
The Fly
Enliven up 20% after Terns Pharmaceuticals agrees to be bought by Merck
1M ago
MRK
ELVN
Enliven price target raised to $45 from $41 at Mizuho
PremiumThe Fly
Enliven price target raised to $45 from $41 at Mizuho
1M ago
ELVN
Enliven Therapeutics: Compelling Early ELVN-001 Data and De-Risked Development Path Support Buy Rating
PremiumRatings
Enliven Therapeutics: Compelling Early ELVN-001 Data and De-Risked Development Path Support Buy Rating
2M ago
ELVN
Enliven Therapeutics: Compelling ELVN-001 CML Data, Strong Cash Runway Support Buy Rating
PremiumRatings
Enliven Therapeutics: Compelling ELVN-001 CML Data, Strong Cash Runway Support Buy Rating
2M ago
ELVN
Enliven reports Q4 EPS (48c), consensus (47c)
PremiumThe Fly
Enliven reports Q4 EPS (48c), consensus (47c)
2M ago
ELVN
Enliven Therapeutics: Robust ELVN-001 CML Data, Clear Pivotal Path, and Solid Cash Runway Support Buy Rating
PremiumRatingsEnliven Therapeutics: Robust ELVN-001 CML Data, Clear Pivotal Path, and Solid Cash Runway Support Buy Rating
4M ago
ELVN
Midday Fly By: Defense stocks surge on Trump budget request
Premium
The Fly
Midday Fly By: Defense stocks surge on Trump budget request
4M ago
F
AA
Enliven reports ‘positive’ initial Phase 1b data for ELVN-001 in CML
Premium
The Fly
Enliven reports ‘positive’ initial Phase 1b data for ELVN-001 in CML
4M ago
ELVN
Enliven announces expected 2026 clinical milestones for ELVN-001
PremiumThe Fly
Enliven announces expected 2026 clinical milestones for ELVN-001
4M ago
ELVN
Enliven Therapeutics appoints new board chair amid transition
PremiumCompany Announcements
Enliven Therapeutics appoints new board chair amid transition
4M ago
8K
ELVN
Enliven Therapeutics Appoints Richard Fair as CEO
PremiumCompany Announcements
Enliven Therapeutics Appoints Richard Fair as CEO
5M ago
8K
ELVN
Enliven announces the appointment of Fair as CEO
PremiumThe Fly
Enliven announces the appointment of Fair as CEO
5M ago
ELVN
Enliven Therapeutics: Strategic Advancements and Promising Clinical Progress Support Buy Rating
PremiumRatingsEnliven Therapeutics: Strategic Advancements and Promising Clinical Progress Support Buy Rating
6M ago
ELVN
Enliven Therapeutics: Promising Financial Discipline and Strategic Positioning Justify Buy Rating
Premium
Ratings
Enliven Therapeutics: Promising Financial Discipline and Strategic Positioning Justify Buy Rating
6M ago
ELVN
Enliven Therapeutics Reports Q3 2025 Financial Results
Premium
Company Announcements
Enliven Therapeutics Reports Q3 2025 Financial Results
6M ago
ELVN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >